PMC:7299399 / 20941-21541 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T94","span":{"begin":5,"end":10},"obj":"Body_part"},{"id":"T95","span":{"begin":74,"end":78},"obj":"Body_part"},{"id":"T96","span":{"begin":389,"end":396},"obj":"Body_part"},{"id":"T97","span":{"begin":528,"end":531},"obj":"Body_part"},{"id":"T98","span":{"begin":536,"end":540},"obj":"Body_part"}],"attributes":[{"id":"A94","pred":"fma_id","subj":"T94","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A95","pred":"fma_id","subj":"T95","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A96","pred":"fma_id","subj":"T96","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A97","pred":"fma_id","subj":"T97","obj":"http://purl.org/sig/ont/fma/fma74412"},{"id":"A98","pred":"fma_id","subj":"T98","obj":"http://purl.org/sig/ont/fma/fma67122"}],"text":" the lungs, with significantly lower levels of respiratory disease and no lung damage compared to control animals, according to a recent article deposited in bioRxiv.69 Another adenoviral vector vaccine developed by CanSino Biological Inc. and Beijing Institute of Biotechnology using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein (Ad5-nCoV) is currently being tested in Phase I/II trials (NCT04398147, NCT04341389, NCT0431312).\nAlthough vaccines based on novel DNA and mRNA technologies might be promising, there are no such kinds of"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T27","span":{"begin":74,"end":78},"obj":"Body_part"}],"attributes":[{"id":"A27","pred":"uberon_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":" the lungs, with significantly lower levels of respiratory disease and no lung damage compared to control animals, according to a recent article deposited in bioRxiv.69 Another adenoviral vector vaccine developed by CanSino Biological Inc. and Beijing Institute of Biotechnology using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein (Ad5-nCoV) is currently being tested in Phase I/II trials (NCT04398147, NCT04341389, NCT0431312).\nAlthough vaccines based on novel DNA and mRNA technologies might be promising, there are no such kinds of"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T76","span":{"begin":47,"end":66},"obj":"Disease"},{"id":"T77","span":{"begin":372,"end":380},"obj":"Disease"},{"id":"T78","span":{"begin":398,"end":401},"obj":"Disease"}],"attributes":[{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0005087"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"}],"text":" the lungs, with significantly lower levels of respiratory disease and no lung damage compared to control animals, according to a recent article deposited in bioRxiv.69 Another adenoviral vector vaccine developed by CanSino Biological Inc. and Beijing Institute of Biotechnology using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein (Ad5-nCoV) is currently being tested in Phase I/II trials (NCT04398147, NCT04341389, NCT0431312).\nAlthough vaccines based on novel DNA and mRNA technologies might be promising, there are no such kinds of"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T211","span":{"begin":5,"end":10},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T212","span":{"begin":74,"end":78},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T213","span":{"begin":74,"end":78},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T214","span":{"begin":106,"end":113},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"},{"id":"T215","span":{"begin":128,"end":129},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T216","span":{"begin":285,"end":286},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T217","span":{"begin":427,"end":433},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":" the lungs, with significantly lower levels of respiratory disease and no lung damage compared to control animals, according to a recent article deposited in bioRxiv.69 Another adenoviral vector vaccine developed by CanSino Biological Inc. and Beijing Institute of Biotechnology using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein (Ad5-nCoV) is currently being tested in Phase I/II trials (NCT04398147, NCT04341389, NCT0431312).\nAlthough vaccines based on novel DNA and mRNA technologies might be promising, there are no such kinds of"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T133","span":{"begin":389,"end":396},"obj":"Chemical"},{"id":"T134","span":{"begin":445,"end":447},"obj":"Chemical"},{"id":"T135","span":{"begin":528,"end":531},"obj":"Chemical"}],"attributes":[{"id":"A133","pred":"chebi_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A134","pred":"chebi_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A135","pred":"chebi_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"}],"text":" the lungs, with significantly lower levels of respiratory disease and no lung damage compared to control animals, according to a recent article deposited in bioRxiv.69 Another adenoviral vector vaccine developed by CanSino Biological Inc. and Beijing Institute of Biotechnology using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein (Ad5-nCoV) is currently being tested in Phase I/II trials (NCT04398147, NCT04341389, NCT0431312).\nAlthough vaccines based on novel DNA and mRNA technologies might be promising, there are no such kinds of"}

{"project":"LitCovid-PubTator","denotations":[{"id":"308","span":{"begin":398,"end":401},"obj":"Gene"},{"id":"309","span":{"begin":383,"end":388},"obj":"Gene"},{"id":"311","span":{"begin":437,"end":447},"obj":"Gene"},{"id":"318","span":{"begin":332,"end":349},"obj":"Species"},{"id":"319","span":{"begin":372,"end":382},"obj":"Species"},{"id":"320","span":{"begin":402,"end":406},"obj":"Species"},{"id":"323","span":{"begin":47,"end":66},"obj":"Disease"}],"attributes":[{"id":"A308","pred":"tao:has_database_id","subj":"308","obj":"Gene:8081"},{"id":"A309","pred":"tao:has_database_id","subj":"309","obj":"Gene:43740568"},{"id":"A318","pred":"tao:has_database_id","subj":"318","obj":"Tax:28285"},{"id":"A319","pred":"tao:has_database_id","subj":"319","obj":"Tax:2697049"},{"id":"A320","pred":"tao:has_database_id","subj":"320","obj":"Tax:2697049"},{"id":"A323","pred":"tao:has_database_id","subj":"323","obj":"MESH:D012140"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" the lungs, with significantly lower levels of respiratory disease and no lung damage compared to control animals, according to a recent article deposited in bioRxiv.69 Another adenoviral vector vaccine developed by CanSino Biological Inc. and Beijing Institute of Biotechnology using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein (Ad5-nCoV) is currently being tested in Phase I/II trials (NCT04398147, NCT04341389, NCT0431312).\nAlthough vaccines based on novel DNA and mRNA technologies might be promising, there are no such kinds of"}